High-Volume HDF improves patient survival
The Catalonian Online Haemodiafiltration Survival Study (ESHOL) published in February 2013 confirms Fresenius Medical Care’s conviction that every patient should be given the chance to benefit from haemodiafiltration (HDF) therapy with high volumes of substitution fluid (HighVolumeHDF). The primary outcome of the study was that HighVolumeHDF therapy significantly improves patient survival compared with conventional dialysis treatment. At this year’s ERA-EDTA Congress, HighVolumeHDF was the main focus of Fresenius Medical Care’s activities.
Therapy modality recently linked to impressive survival figures
In view of the recently published ESHOL study (Estudio de Supervivencia de Hemodiafitracion On-Line; On-Line Haemodiafiltration Survival Study) demonstrating that High Volume On-Line Hemodiafiltration (OL-HDF) therapy improves patients’ survival rate1, we would like to draw your attention towards our award winning 5008 therapy system.
The new Catalonian High-Volume Online Haemodiafiltration (OL-HDF) study shows that High-Volume OL-HDF therapy improves patient’s survival rate. With a 30% reduction of all-cause mortality and 33% lower risk of cardiovascular mortality patients should benefit from High-Volume Online HDF.
Meet our Singapore team at Tan Tock Seng Hospital
World Kidney Day's (WKD) aim is to raise awareness of the importance of the kidneys to the overall health of the population and to reduce the frequency and impact of kidney disease and its associated health problems worldwide. WKD is a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF).
Welcome to Fresenius Medical Care (FME) Connect, your new quarterly e-newsletter! We want to update you on a variety of renal topics ranging from the latest scientific news to our company product updates and worldwide renal events.